Global Albumin Market Overview
Albumin Market accounted for USD 4.29 Billion in 2018 and is estimated to be 6.77 Billion by 2026 and is anticipated to register a CAGR of 60.6%.
Albumin is found in blood plasma and is the most abundant protein. It aids a wide range of functions such as transporting fatty acids and hormones and maintains oncotic pressure. Different types of serum albumin are widely utilized for clinical applications. Bovine serum albumin and human serum albumin and are obtained from bovine plasma and human plasma, respectively. Whereas, recombinant albumin is produced by recombinant techniques in bacteria and yeast strains. Intensely, it helps restore blood volume by replacing the lost fluid and due to burns, trauma, surgeries, or infections and liver diseases. It severs in the stabilization of drugs by plummeting oxidation, aggregation, and surface absorption.
Global Albumin Market Drivers & Restraints
High occurrence of liver disease
As per the report published by Centers for Disease Control and Prevention, numbers of people diagnosed suffering from liver disease were 4.9 million in the U.S. This indicates the requirement of people suffering from a state where their livers are not able to produce albumin anymore. This is projected to root substantial demand for the product, owing to its important nature in major bodily functions such as transportation of essential minerals, vitamins, and hormones.
Stringent government regulation
Instead to growing prevalence’s of hypoalbuminemia and hypovolemia worldwide, certain factors such as lower availability of therapeutic products and strict government norms are hampering the adoption of albumin. Further, stringent government regulation imposed on producing therapeutic applications is one of the major restraining factor for the target market. For instance, the government of U.S., ensures that the plasma collected and distributes undergoes the international standards of safety, quality, and potency.
Global Albumin Market Segmentations & Regional Insights
The albumin market is segmented based on product, application, and region.
On the basis of Product, the albumin market is segmented into human serum albumin, bovine serum albumin, and recombinant albumin. On the basis of application, the target market is classified into therapeutics, drug formulation & vaccine, component of media, and other applications.
Regional Insights:
On region the albumin market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America was the dominating revenue supplier to the albumin market in 2017, and is projected to lead the market over long run. This is accredited to the early approval of albumin products and increased adoption of recombinant albumin in this region. Moreover, Asia-Pacific is projected to witness at the biggest CAGR over the study period, owing to surge in healthcare expenditure, rise in affordability, and growth in awareness toward albumin products.
Report Scope:
Attribute |
Details |
Base year for estimation |
2018 |
Forecast period |
2018 – 2026 |
Market representation |
Revenue in USD Billion & CAGR from 2018 – 2026 |
Market Segmentation |
By Product - Human Serum Albumin, Bovine Serum Albumin, and Recombinant Albumin By Application- Fuel Cell, Lithium-Ion, Lithium Polymer, and Nickel Cadmium |
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered in the Report:
This report forecasts revenue growth at , regional, and country levels and provides an analysis of the latest application trends and opportunities in each of the sub-segments from 2019 to 2026. For the purpose of this study, has segmented the albumin market report based on product, application, and region.
Albumin Market, By Product:
- Human Serum Albumin
- Bovine Serum Albumin
- Recombinant Albumin
Albumin Market, By Application:
- Therapeutics
- Drug Formulation & Vaccine
- Component of Media
- Other Applications
Albumin Market, By Region:
- North America
- Middle East & Africa
-
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
-
- Latin America
-
- Brazil
- Mexico
- Rest of Latin America
-
- Asia Pacific
-
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
-
- Europe
-
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
-
- U.S.
- Canada
- Middle East & Africa
Global Albumin Market Competitive Landscape & Key Players
The key players operating the albumin market includes Grifols S.A., China Biologic Products Inc., Ventria Bioscience, Shire Plc, Merck KGaA, CSL Limited, Octapharma AG, Albumedix Ltd., Thermo Fisher Scientific, and Baxter International Inc. Prominent players in the market are dominating and producing innovative products. For instance, CSL Limited is among the leading companies having about 30% share in the target market due to acquisitions of Chinese players in the market. CSL has expanded its commercial footprint across the China leading to higher sales volume of the drugs.
Global Albumin Market Company Profile
- Grifols S.A.
- China Biologic Products Inc.
- Ventria Bioscience
- Shire Plc
- Merck KGaA
- CSL Limited
- Octapharma AG
- Albumedix Ltd.
- Thermo Fisher Scientific
- Baxter International Inc.
FAQs
The global albumin market is segmented based on the product, application, sales channel, and region.
The high occurrence of liver disease is demanding the growth of the global albumin market globally.
North America was the dominating revenue supplier to the global albumin market in 2017 and is projected to lead the global market over the long run. This is accredited to the early approval of albumin products and increased adoption of recombinant albumin in this region.
Prominent players in the global market are dominating and producing innovative products. For instance, CSL Limited is among the leading companies having about 30% share in the target market due to acquisitions of Chinese players in the market. CSL has expanded its commercial footprint across China leading to the higher sales volume of the drugs.